1. Siegel, R., Desantis, C. & Jemal, A. Colorectal cancer statistics, 2014. CA Cancer J Clin 64, 104–117 (2014).
2. Van Cutsem, E., Cervantes, A., Nordlinger, B. & Arnold, D. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25, 1–9 (2014).
3. Hegewisch-Becker, S. et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 16, 1355–1369 (2015).
4. Ferrara, N. & Adamis, A. P. Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Discov. 15, 385–403 (2016).
5. Aghajanian, C. et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 139, 10–16 (2015).
6. Prasad, V., De Jesús, K. & Mailankody, S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol 14, 381–390 (2017).
7. Goldstein, D. A., Zeichner S. B., Bartnik C. M., Neustadter, E. & Flowers, C. R. Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies. Clin Colorectal Cancer 15, 1–6 (2016).
8. Cassidy, J. et al. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol 136, 737–743 (2010).
9. Pfaendler, K. S., Liu, M. C. & Tewari, K. S. Bevacizumab in Cervical Cancer. Cancer J 24, 187–192 (2018).
10. Ma, H. et al. Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis. Med. 98, e18227 (2019).
11. Bennouna, J. et al. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT). Clin Colorectal Cancer 16, 129-140.e4 (2017).
12. Khakoo, S. et al. ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. Clin Colorectal Cancer 18, 280-291.e5 (2019).
13. Xu, W. et al. Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis. Onco Targets Ther 9, 4833–4842 (2016).
14. Botrel, T. E. A., Clark, L. G. O., Paladini, L. & Clark, O. A. C. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer 16, 677 (2016).
15. Welch, S., Spithoff, K., Rumble, R. B., Maroun, J. & Gastrointestinal Cancer Disease Site Group. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 21, 1152–1162 (2010).
16. Qu, C. Y. et al. Value of bevacizumab in treatment of colorectal cancer: A meta-analysis. World J Gastroenterol 21, 5072–5080 (2015).
17. Iwasa, S. et al. Lack of association of proteinuria and clinical outcome in patients treated with bevacizumab for metastatic colorectal cancer. Anticancer Res 33, 309–316 (2013).
18. Wu, S., Kim, C., Baer, L. & Zhu, X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 21, 1381–1389 (2010).
19. Zhao, T., Wang, X., Xu, T., Xu, X. & Liu, Z. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget 8, 51492–51506 (2017).
20. Zhu, X., Wu, S., Dahut, W. L. & Parikh, C. R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49, 186–193 (2007).
21. Tanaka, H. et al. Hypertension and Proteinuria as Predictive Factors of Effects of Bevacizumab on Advanced Breast Cancer in Japan. Biol Pharm Bull 41, 644–648 (2018).
22. Lalami, Y. & Klastersky, J. Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data. Crit Rev Oncol Hematol 120, 163–179 (2017).
23. Crawford, J., Dale, D. C. & Lyman, G. H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100, 228–237 (2004).
24. Oblak, I. et al. The impact of anaemia on treatment outcome in patients with squamous cell carcinoma of anal canal and anal margin. Radiol Oncol 50, 113–120 (2016).
25. Wilson, M. J. et al. Long-term prognostic value of preoperative anemia in patients with colorectal cancer: A systematic review and meta-analysis. Surg Oncol 26, 96–104 (2017).
26. An, M. S. et al. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy. World J Surg Oncol 13, 64 (2015).
27. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45, 228–247 (2009).
28. Demircan, N. C. et al. Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy. J BUON 24, 1494–1500 (2019).
29. Shitara, K. et al. Prognostic factors for metastatic colorectal cancer patients undergoing irinotecan-based second-line chemotherapy. Gastrointest Cancer Res 4, 168–172 (2011).
30. Fendler, W. P. et al. Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancer. Eur Radiol 25, 2693–2700 (2015).
31. Jubb, A. M. et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24, 217–227 (2006).
32. Bernaards, C. et al. Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: analysis of phase III studies. J Clin Oncol 28, 10519 (2010).
33. Duda, D. G. Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer. ISRN cell Biol. 2012, 587259 (2012).
34. Zee, Y. K. et al. Hypertension (HTN) and proteinuria (PTN) as biomarkers of efficacy in antiangiogenic therapy for metastatic colorectalcancer (mCRC). J Clin Oncol 28, e13580 (2010).
35. Feliu, J. et al. Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer. PLoS One 10, e0116527 (2015).
36. Lee, C. S., Alwan, L. M., Sun, X., McLean, K. A. & Urban, R. P. Routine proteinuria monitoring for bevacizumab in patients with gynecologic malignancies. J Oncol Pharm Pract. 22, 771–776 (2016).
37. Teramachi, H. et al. Risk factors contributing to urinary protein expression resulting from bevacizumab combination chemotherapy. Pharmazie 68, 217–220 (2013).
38. Lafayette, R. A. et al. Incidence and relevance of proteinuria in bevacizumab-treated patients: pooled analysis from randomized controlled trials. Am J Nephrol 40, 75–83 (2014).
39. Izzedine, H. et al. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 46, 439–448 (2010).
40. Eremina, V. et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358, 1129–1136 (2008).
41. Lambrechts, D. et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol. 13, 724–733 (2012).
42. Garcia-Donas, J. et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 12, 1143–1150 (2011).
43. Hansen, T. F. et al. The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer. Int. J. Colorectal Dis. 27, 715–720 (2012).
44. Schneider, B. P. et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26, 4672–4678 (2008).
45. Nikzamir, A., Esteghamati, A., Hammedian, A. A. & Mahmoudi, T. The role of vascular endothelial growth factor +405 G/C polymorphism and albuminuria in patients with type 2 diabetes mellitus. Mol Biol Rep 39, 881–886 (2012).
46. Caro, J. J., Salas, M., Ward, A. & Goss, G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91, 2214–2221 (2001).
47. Valentini, V. et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 29, 3163-3172 (2011).
48. Peng, J. et al. Prognostic nomograms for predicting survival and distant metastases in locally advanced rectal cancers. PLoS One 9, e106344 (2014).
49. Köhne, C. H. et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13, 308–317 (2002).
50. Hegewisch-Becker, S. et al. Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial. Eur J Cancer 101, 105–113 (2018).